• Current Issue:
    4articles Vol.5(2024)
    Sort by
    Latest
    Open Access
    Perspective
    Resistance to immune checkpoint inhibitors in colorectal cancer with deficient mismatch repair/microsatellite instability: misdiagnosis, pseudoprogression and/or tumor heterogeneity?
    Colorectal carcinoma (CRC) with deficiency of the deficient mismatch repair (dMMR) pathway/ microsatellite instability (MSI) is characterized by a high mutation load and infiltration of immune cells [...] Read more.
    Nicola Normanno ... Carmine Pinto
    Published: May 23, 2024 Explor Target Antitumor Ther. 2024;5:495–507
    DOI: https://doi.org/10.37349/etat.2024.00231
    View:114
    Download:2
    Times Cited: 0
    Open Access
    Review
    Advancements and recent explorations of anti-cancer activity of chrysin: from molecular targets to therapeutic perspective
    In recent times, there have been notable advancements in comprehending the potential anti-cancer effects of chrysin (CH), a naturally occurring flavonoid compound found abundantly in various plant s [...] Read more.
    Abhilasha Sood ... Manoj Kumar
    Published: May 23, 2024 Explor Target Antitumor Ther. 2024;5:477–494
    DOI: https://doi.org/10.37349/etat.2024.00230
    This article belongs to the special issue Molecular Targeted Therapy for Cancer
    View:147
    Download:13
    Times Cited: 0
    Open Access
    Perspective
    Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors
    Thymic epithelial tumors (TETs) are rare malignant neoplasms arising in the thymus gland. Nevertheless, TETs, including thymomas (TMs), thymic carcinomas (TCs), and thymic neuroendocrine neoplasms ( [...] Read more.
    Stefano Lucà ... Renato Franco
    Published: May 21, 2024 Explor Target Antitumor Ther. 2024;5:465–476
    DOI: https://doi.org/10.37349/etat.2024.00229
    This article belongs to the special issue Molecular Diagnosis and Personalized Therapy of Cancer
    View:93
    Download:8
    Times Cited: 0
    Open Access
    Review
    Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach
    Recently, the development of targeted therapy approaches such as those based on tyrosine kinase inhibitor (TKI) greatly improved the clinical outcomes of patients affected by oncogene addicted advan [...] Read more.
    Francesca Di Pressa ... Alessio Bruni
    Published: May 17, 2024 Explor Target Antitumor Ther. 2024;5:449–464
    DOI: https://doi.org/10.37349/etat.2024.00228
    This article belongs to the special issue Integrated Approaches for Non-Small-Cell Lung Cancer
    View:118
    Download:8
    Times Cited: 0